Key Points
- Odyssey Therapeutics director Dimension Capital II, L.P. bought 1,111,111 shares at $18.00 each, totaling nearly $20 million. The purchase increased its holdings by 50%, signaling strong confidence in the company.
- Multiple other insiders also bought shares, including Director Nan (Ln) Li, Director Shelley Chu, CFO Jason Haas, and Director Jeffrey M. Leiden. The broad insider buying suggests a coordinated bullish signal from management and the board.
- ODTX stock rose 2.6% and opened at $17.90, trading within a 12-month range of $15.35 to $20.30. The article notes a small insider sale, but it was minor compared with the larger purchases.
Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Get Free Report) Director Dimension Capital Ii, L.P. bought 1,111,111 shares of the company's stock in a transaction on Friday, May 8th. The stock was bought at an average price of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the purchase, the director owned 3,333,516 shares of the company's stock, valued at approximately $60,003,288. The trade was a 50.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Odyssey Therapeutics Trading Up 2.6%
Shares of ODTX stock opened at $17.90 on Wednesday. Odyssey Therapeutics, Inc. has a 12-month low of $15.35 and a 12-month high of $20.30.
Key Headlines Impacting Odyssey Therapeutics
Here are the key news stories impacting Odyssey Therapeutics this week:
- Positive Sentiment: Director Dimension Capital II, L.P. disclosed a large purchase of 1,111,111 shares, increasing its ownership by 50%. This is the biggest recent insider buy and could be seen as a strong vote of confidence. SEC filing
- Positive Sentiment: Director Nan (Ln) Li also bought 1,111,111 shares, another sizable insider purchase that reinforces the bullish insider signal. SEC filing
- Positive Sentiment: Several other insiders added stock, including Director Shelley Chu, CFO Jason Haas, and Director Jeffrey M. Leiden. Coordinated buying across management and the board often supports investor confidence. Article
- Neutral Sentiment: A broader healthcare IPO report noted that healthcare listings raised $4.7 billion, with Odyssey Therapeutics mentioned as one of the IPO debuts that slipped. This is more of a sector market backdrop than a company-specific catalyst. Article
- Negative Sentiment: The only insider sale in the news flow was a small 1,780-share sale by SR One Capital Management, but it was minor compared with the much larger purchases, so it is unlikely to outweigh the bullish effect of the buying. SEC filing
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
